Does Aetna Cover GLP-1 Medications? (2026)
Coverage rules, copays, prior auth requirements, and appeal options for Aetna members seeking Wegovy, Ozempic, Zepbound, or Mounjaro.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Coverage by Medication[8]
| Medication | Aetna Coverage |
|---|---|
| Wegovy (semaglutide) | Aetna covers Wegovy on Non-Medicare commercial plans under bulletin 4774-C UDR 08-2023 v2 (effective 05/01/2024). Adult initial criteria: patient must be >=18, have BMI >=30 (or BMI >=27 with one weight-related comorbidity), and have participated in a comprehensive weight-management program for at least 6 months prior to drug therapy. Initial approval is 7 months; continuation/reauthorization is 12 months and requires documented loss of at least 5% of baseline body weight (or maintained 5% loss). Pediatric (12-17): BMI in the 95th percentile or greater + 6-month program. Wegovy also has a separate cardiovascular risk-reduction pathway in 4774-C for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) made Wegovy its preferred commercial GLP-1 in July 2025; from October 1, 2026 its template commercial formularies carry Zepbound again as an additional preferred option alongside Wegovy, though plan sponsors may customize. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days. |
| Ozempic (semaglutide) | Aetna covers Ozempic for type 2 diabetes per bulletin 2439-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA requires the patient is NOT on stable GLP-1 maintenance >=3 months AND meets one of: (1) inadequate response, intolerance, or contraindication to metformin; (2) requires combination therapy AND has A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction since starting GLP-1 therapy. Aetna Medicare Part D plans cover Ozempic for type 2 diabetes (NOT for off-label weight loss). Quantity limits vary by strength: 2 mg/1.5 mL = 1 pen per 21 days; 4 mg/3 mL and 8 mg/3 mL = 1 pen per 21 days. Verbatim MACE language in the bulletin: 'reduce the risk of major adverse cardiovascular events…in adults with type 2 diabetes mellitus and established cardiovascular disease.' |
| Zepbound (tirzepatide) | Aetna covers Zepbound on Non-Medicare commercial plans per bulletin 6947-C P04-2025 (effective 07/01/2025), which supersedes the older 6192-C. Adult criteria: BMI >=30 OR BMI >=27 with one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia), plus participation in a comprehensive weight-management program for at least 6 months prior to drug therapy. Continuation requires documented >=5% baseline body-weight loss. Separate OSA pathway covers moderate-to-severe OSA in adults with obesity (AHI >=15 events/hour). CRITICAL CAVEAT: a separate Zepbound Exception bulletin 6981-A P04-2025 applies on plan-formulary codes ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC where Wegovy is the preferred step. CVS Caremark removed Zepbound from most commercial formularies in July 2025 in favor of Wegovy, then added it back as an additional preferred option on October 1, 2026, so the 6981-A exception step may no longer apply on Caremark template plans. Aetna Medicare Part D does NOT cover Zepbound for weight loss (statutory exclusion); may cover for OSA indication. Beginning 07/01/2026, only the Zepbound KwikPen formulation (NOT vials/single-dose pens) is available to MA-PD members via the CMS Medicare GLP-1 Bridge. Quantity limits all strengths: 2 mL (1 package of 4 pens) per 21 days; 6 mL (3 packages of 4 pens) per 63 days. |
| Mounjaro (tirzepatide) | Aetna covers Mounjaro for type 2 diabetes per bulletin 5468-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA verbatim: 'The patient has NOT been receiving a stable maintenance dose of the requested drug for at least 3 months and ONE of the following criteria are met' — either metformin inadequacy/intolerance/contraindication, OR combination therapy AND A1C >=7.5%. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction (approval period 36 months). Aetna Medicare Part D plans cover Mounjaro for type 2 diabetes (NOT for off-label weight loss). Quantity limits: 4 single-dose pens or vials (2 mL) per 21 days OR 12 single-dose pens or vials (6 mL) per 63 days. |
| Foundayo (orforglipron) | Aetna covers Foundayo (orforglipron) on non-Medicare commercial plans per bulletin 7433-C P04-2026. Criteria: BMI >=30, or BMI >=27 with a weight-related comorbid condition, plus participation in a comprehensive weight-management program for at least 6 months before drug therapy. Initial approval is 8 months; continuation is 12 months. Quantity limit: 30 tablets per 25 days. For Aetna Medicare Part D members, Foundayo is included in the CMS Medicare GLP-1 Bridge at a $50 copay from 07/01/2026 through 12/31/2027. Bridge eligibility is tiered: BMI >=35 alone; BMI >=30 with diastolic heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; or BMI >=27 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or fatty liver disease, or whose GLP-1 is already covered by Part D, are excluded. |
| Saxenda (liraglutide) | Aetna covers Saxenda (liraglutide for chronic weight management) per bulletin 1227-C P08-2024_R (12/19/2024). Adult criteria: BMI >=30, or BMI >=27 with at least one weight-related comorbid condition (verbatim list: hypertension, type 2 diabetes mellitus, or dyslipidemia), AND participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy. Pediatric (12-17): BMI corresponding to >=30 kg/m^2 for adults by international cut-offs (Cole Criteria) + 6-month program. CRITICAL DIFFERENCE FROM WEGOVY/ZEPBOUND: Saxenda continuation requires loss of >=4% of baseline body weight (NOT 5%), or maintained 4% loss. Pediatric continuation requires >=1% reduction in BMI from baseline. Saxenda is NOT included in the CMS Medicare GLP-1 Bridge effective 07/01/2026. Quantity limits: 15 mL (1 package of five 3 mL pens) per 25 days; 45 mL (3 packages) per 75 days. |
| Typical copay (when covered) | $25-$80 / month |
If You're Denied by Aetna
If Aetna denies coverage for Wegovy or Zepbound, you still have affordable options. Compounded semaglutide and tirzepatide are dispensed by licensed 503A pharmacies[7] and cost $149-$299/month — a fraction of brand-name pricing. Brand-name GLP-1 medications are generally an HSA/FSA-eligible medical expense with a prescription[5], and many plan administrators also accept compounded GLP-1s with a Letter of Medical Necessity. The providers below ship to all 50 states and offer same-week prescriptions.
Many large employers offer self-funded health plans governed by ERISA rather than state insurance law, which gives them discretion over whether to cover anti-obesity medications[6]. If your employer self-funds its plan, check the Summary Plan Description for the specific GLP-1 coverage language.
Before going cash-pay, file a formal appeal with Aetna. Many denials are overturned with a Letter of Medical Necessity from your prescriber documenting BMI, comorbidities, and prior failed weight-loss attempts.
For the literal text of every Aetna GLP-1 bulletin — the 7-month Wegovy reauth window, the 4% Saxenda continuation threshold (NOT 5%), the Zepbound 6981-A exception on plan codes ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC, the Mounjaro/Ozempic metformin-first step rule, the CVS Caremark July-2025 Wegovy-preferred formulary swap (the dominant 2026 denial driver), the Foundayo handling, and the CMS Medicare GLP-1 Bridge starting 07/01/2026 — see our Aetna GLP-1 Prior Authorization Guide.
Top cash-pay GLP-1 providers if Aetna won't cover it
Compounded semaglutide and tirzepatide are widely available on a cash-pay basis — often for less than a plan's copay after a denial. These are our top-ranked picks, followed by a fuller list of alternatives.
Top picks
| # | Provider | Score | |
|---|---|---|---|
| 1 | CoreAge Rx | Get started | |
| 2 | Collective | Get started | |
| 3 | Found | Get started | |
| 4 | Gala | Get started | |
| 5 | bmiMD | Get started |
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
From /mo$79Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
the lowest flat medication price if you can absorb an annual membership fee
From /mo$59Flat at every doseCoverage44 statesMedicationsSemaglutideTirzepatide - Nationwide Coverage
medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
From /mo$149Coverage50 statesMedicationsSemaglutideTirzepatideOrforglipron compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatideone flat compounded GLP-1 price at every dose: semaglutide $159/mo month to month, $119/mo on a 12-month plan
From /mo$159Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
| ★ Editor's Pick lowest-price compounded semaglutide and tirzepatide with one flat price at every dose | $79 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → | |
| Best Budget the lowest flat medication price if you can absorb an annual membership fee | $59 Flat pricing | SemaglutideTirzepatide | 44 states | Get started → | |
| Nationwide Coverage medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help | $149 | SemaglutideTirzepatideOrforglipron | 50 states | Get started → | |
compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → | |
one flat compounded GLP-1 price at every dose: semaglutide $159/mo month to month, $119/mo on a 12-month plan | $159 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → |
More compounded alternatives
Editorial score · methodology
Aurelius Health Group
Best for: transparent, care-inclusive compounded tirzepatide microdosing
Editorial score · methodology
Boston Medical Group
Best for: men's health brand selling compounded semaglutide or tirzepatide at one flat price across every dose
Editorial score · methodology
Broose Wellness
Best for: people who want compounded semaglutide or tirzepatide with lifestyle coaching and posted prices
Editorial score · methodology
Editorial score · methodology
Chronos Body Health & Wellness
Best for: physician-led GLP-1 care with brand-name and microdosing options
Editorial score · methodology
Get StartedRead full Chronos Body Health & Wellness review →Found
Best for: medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Editorial score · methodology
Found Youth
Best for: choosing between injection, microdose and sublingual formats of either GLP-1
Editorial score · methodology
Heros Health
Best for: Low, published prices on compounded semaglutide and tirzepatide with no membership fee
Editorial score · methodology
Hims
Best for: people who want brand-name GLP-1 pills or pens through a big-name app with 24/7 messaging
Editorial score · methodology
Editorial score · methodology
Iron Med RX
Best for: oral or injectable compounded GLP-1, one provider, account-gated pricing
Editorial score · methodology
Ironvale RX
Best for: compounded GLP-1s with nausea medicine bundled in and no charge unless a clinician approves you
Editorial score · methodology
KairoRx
Best for: people who want compounded GLP-1s alongside peptide and hormone treatments from one telehealth brand
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: Irving/Dallas patients wanting in-person, physician-led weight loss care
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Robinhood Telehealth
Best for: budget compounded semaglutide or tirzepatide with flat dose pricing and a microdose option
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
SUROS Rx
Best for: published monthly and quarterly compounded GLP-1 prices with a named medical group and pharmacy
Editorial score · methodology
The Protocole
Best for: people who want compounded semaglutide or tirzepatide alongside other peptide therapies in one place
Editorial score · methodology
Tomorrow
Best for: people who want compounded GLP-1 injections or under-the-tongue drops on a true monthly plan
Editorial score · methodology
TomorrowsRX
Best for: people who want low per-month prices on prepaid compounded semaglutide or tirzepatide supplies
Editorial score · methodology
Editorial score · methodology
Vyvron
Best for: a locked founding rate from a platform that names its clinical partner and holds a real LegitScript seal
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Aetna Coverage Updates
Get notified when Aetna GLP-1 coverage rules change.
Sources & methodology (as of November 2026)
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.Weight Loss Rankings insurer coverage index (manually curated formulary data)— Weight Loss Rankings.